Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Randall Spotlights Surgical and Non-Surgical Advances in Musculoskeletal Oncology

September 12th 2023

R. Lor Randall, MD, FACS, discusses the process of organizing the symposium, key surgical and non-surgical advancements as well as socioeconomic disparities identified in these papers, and the importance of this information for both surgical and medical oncologists.

Addition of Doxorubicin to Zalifrelimab/Balstilimab Leads to Responses in Advanced Soft Tissue Sarcoma

August 24th 2023

Breelyn Wilky, MD, discusses the rationale for investigating the addition of doxorubicin to zalifrelimab and balstilimab in patients with advanced/metastatic soft tissue sarcoma, expands on results from the phase 2 trial, and emphasizes the need for continued research for the potential role of immunotherapy in this patient population.

Dr Van Tine on the SPEARHEAD-1 Trial of Afami-Cel in Advanced Synovial Sarcoma

August 17th 2023

Brian A. Van Tine, MD, PhD, discusses findings from the overall survival analysis of the phase 2 SPEARHEAD-1 trial in patients with advanced synovial sarcoma.

Randall Discusses the Importance of Identifying and Managing Chondroblastoma in Clinical Practice

August 16th 2023

R. Lor Randall, MD, FACS, explains the difference between noncancerous chondroblastoma and other bone neoplasms, details the typical diagnosis and treatment of this rare condition, and emphasizes the importance of pediatric and medical oncologists being able to identify it in clinic.

Pembrolizumab Monotherapy Displays Efficacy in Rare Sarcomas

August 9th 2023

The PD-1 inhibitor pembrolizumab displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes.

Camsirubicin Reduces Tumor Size in Advanced Soft Tissue Sarcoma

August 8th 2023

Treatment with camsirubicin led to a reduction in tumor size in patients with advanced soft tissue sarcoma.

FDA Green Lights Companion Diagnostic for Avapritinib in Gastrointestinal Stromal Tumors

August 8th 2023

The FDA has approved the therascreen PDGFRA RGQ PCR kit for use as a companion diagnostic, co-developed by Qiagen and Blueprint Medicines, to assist in the identification of patients with gastrointestinal stromal tumors who may be candidates to receive avapritinib.

Global Consensus-Finding Meeting Aims to Improve the Management of Chondrosarcoma Complications

August 4th 2023

R. Lor Randall, MD, FACS, provides details about the 2024 Birmingham Orthopedic Oncology Meeting and its main topic of discussion, explains the rationale for its inception, and emphasizes the importance of this meeting for orthopedic oncologists treating chondrosarcoma.

ASCO Presentations Indicate Bright Future For Immunotherapy Combinations in Soft Tissue Sarcoma

July 31st 2023

Jonathan C. Trent, MD, PhD, discusses data from 2 phase 2 trials of immunotherapy in soft tissue sarcoma, as well as their clinical significance.

Theseus Pharmaceuticals Terminates Development of THE-630 in Gastrointestinal Stromal Tumors

July 19th 2023

Theseus Pharmaceuticals has announced that the development of THE-630 as a potential therapeutic option for patients with gastrointestinal stromal tumor has been terminated, and enrollment to the ongoing phase 1/2 trial evaluating the agent’s safety and efficacy in this population has been discontinued.

Dr Brohl on the Safety and Efficacy of IFx-Hu2.0 in MCC and CSCC

July 5th 2023

Andrew S. Brohl, MD, discusses the safety and immunologic responses with intratumoral administration of Idx-Hu2.0 in patients with advanced Merkel cell carcinoma and cutaneous squamous cell carcinoma.

Dr Wilky on the Study of Zalifrelimab, Balstilimab, and Doxorubicin in Soft Tissue Sarcoma

June 27th 2023

Breelyn A. Wilky, MD, discusses the rationale for investigating the combination of zalifrelimab, balstilimab, and doxorubicin in patients with advanced/metastatic soft tissue sarcoma, and early results from a phase 2 trial.

Dr Reed on the Investigation of Trastuzumab Deruxtecan in HER2+ Osteosarcoma

June 27th 2023

Damon R. Reed, MD, discusses a phase 2 study of fam-trastuzumab deruxtecan-nxki in adolescent and young adult patients with recurrent HER2-positive osteosarcoma.

Pazopanib Associated With Higher Wound Complication Rates in Non-rhabdomyosarcoma Soft Tissue Sarcoma

June 20th 2023

R. Lor Randall, MD, FACS, discusses the use of neoadjuvant pazopanib in patients with non-rhabdomyosarcoma soft tissue sarcoma, expanded on findings from the subgroup analysis of ARST1321, and detailed the implications of these findings.

Dr Randall on One-stage Synovectomy in D-TGCT

June 14th 2023

R. Lor Randall, MD, FACS, discusses findings from a study of one-stage synovectomy in patients with diffuse-type tenosynovial giant cell tumor of the knee.

One-stage Synovectomy Does Not Lead to Worse Outcomes in D-TGCT of the Knee

June 14th 2023

R. Lor Randall, MD, FACS, discusses the standard treatment approach for patients with diffuse-type tenosynovial giant cell tumor, the results of the retrospective cohort study evaluating 1- vs 2-stage synovectomies in these patients, and the importance of having additional treatment options for this patient population.

Lurbinectedin Plus Doxorubicin Shows Early Efficacy and Safety in Soft Tissue Sarcomas

June 12th 2023

A full dose of lurbinectedin plus a low dose of doxorubicin was clinically active and tolerable in patients with advanced or metastatic soft tissue sarcomas, supporting its continued investigation in those with leiomyosarcoma.

Dr Van Tine on Investigating Cabozantinib With PD-1 and CTLA-4 Inhibition in Sarcoma

June 9th 2023

Brian A. Van Tine, MD, PhD, discusses the rationale for launching a randomized phase 2 trial investigating cabozantinib combined with nivolumab and ipilimumab vs cabozantinib alone in metastatic soft tissue sarcoma and discusses key findings from the trial.

Dr Kasper on the Evaluation of Nirogacestat in Desmoid Tumors in the DeFi Trial

June 9th 2023

Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, Mannheim, discusses the effect of nirogacestat on tumor volume and T2 hyperintensity in patients with desmoid tumors.

FDA Extends Review Period for Nirogacestat NDA in Desmoid Tumors

June 8th 2023

The FDA has extended the Prescription Drug User Fee Act decision date by 3 months to allow more time to complete their review of the new drug application seeking the approval of nirogacestat in the treatment of adult patients with desmoid tumors.